Regulatory Update

ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. ISPE President/CEO Fireside Chat with FDA Commissioner A fireside chat...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Regulators on Trust, Collaboration, Reliance, Harmonization...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Barriers to Innovation: Your Input Requested ISPE has launched a...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. ISPE Launches Initiative on Enabling Global Pharma Innovation Enabling...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. ISPE’s Advancing Pharmaceutical Quality (APQ) Program Fully Launched...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Are you ready to implement ICH Q9(R1)? That question was at the heart...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Regulator/Industry Panels at ISPE European Annual Conference A panel...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Industry Study Finds Divergence in Regulators’ Interpretation of ICH...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. US FDA and WHO Highlight Agility and Collaboration at ISPE Annual...
ISPE is committed to fostering communications and interactions to advance common interests among the pharmaceutical industry and regulatory agencies. Global Regulators and Industry discuss Shared Responsibility for QRM...